Immunocore (IMCR) Expected to Post Quarterly Earnings on Thursday

Immunocore (NASDAQ:IMCR) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Immunocore to post earnings of ($0.01) per share and revenue of $148.2150 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.51. The business had revenue of $106.68 million for the quarter, compared to analyst estimates of $145.20 million. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. The firm’s revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 EPS. On average, analysts expect Immunocore to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Immunocore Stock Performance

NASDAQ IMCR opened at $32.43 on Tuesday. Immunocore has a twelve month low of $27.56 and a twelve month high of $40.71. The company has a quick ratio of 4.15, a current ratio of 4.18 and a debt-to-equity ratio of 1.00. The stock has a market cap of $1.65 billion, a P/E ratio of -58.96 and a beta of 0.74. The company’s 50-day simple moving average is $31.26 and its 200 day simple moving average is $31.32.

Analysts Set New Price Targets

A number of research firms have weighed in on IMCR. Mizuho lifted their price objective on Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a report on Monday. Wall Street Zen downgraded Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a research report on Friday, July 17th. Zacks Research cut Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $100.00 price target on shares of Immunocore in a research report on Monday, April 20th. Five equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $56.29.

Institutional Trading of Immunocore

Hedge funds and other institutional investors have recently modified their holdings of the stock. Arax Advisory Partners boosted its position in Immunocore by 302.9% in the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after buying an additional 1,042 shares during the last quarter. Osaic Holdings Inc. raised its position in shares of Immunocore by 117.4% during the second quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock worth $97,000 after acquiring an additional 1,700 shares during the last quarter. State of Tennessee Department of Treasury acquired a new position in shares of Immunocore during the second quarter valued at $132,000. Federation des caisses Desjardins du Quebec lifted its stake in shares of Immunocore by 162.1% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 5,478 shares of the company’s stock valued at $190,000 after acquiring an additional 3,388 shares during the period. Finally, Cetera Investment Advisers acquired a new position in shares of Immunocore during the fourth quarter valued at $203,000. Institutional investors and hedge funds own 84.50% of the company’s stock.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.